**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:** CAN/2015-16/653

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | LAMIVUDINE, NEVIRAPINE & ZIDOVUDINE TABLETS 150 mg/200 mg/300 mg | | REF. NO: NDQD201603783 |
| **DATE RECEIVED:** 04.03.2016 | **LABEL CLAIM:** | Each film coated tablet contains 150 mg of Lamivudine USP, 200 mg of Nevirapine USP and 300 mg of Zidovudine USP. | |
| **BATCH NO.:** E140773 | **PRESENTATION:** | Off white coloured, caplet-shaped, biconvex faced tablets, embossed '3' on one face and 'H' on the other face, packed in a white plastic multi-dose container carrying 60 tablets in a unit box. | |
| **MGF. DATE:** Apr. 2014 | **MANUFACTURER:** | HETERO Labs Limited. | |
| **EXP. DATE:**  Mar. 2017 | **ADDRESS:** | 22-110, I.D.A., Jeedimetla, Hyderabad - 500 055, INDIA. | |
| **CLIENT REF NO:** | **CLIENT:** | WHO - SOMALIA, WHO-SOMALIA liaison Office, Nairobi, KENYA | |
|  | **TEST(S) REQUESTED:** | Uniformity of Weight, Identification, Dissolution, Assay | |

**RESULTS**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPEDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Weight** | Weight | BP 2016 Vol. V App XII C | NMT 2 tablets deviate by more than 5% from mean tablet weight | None Deviates | **COMPLIES** |
| **Identification** | HPLC | Adopted In-House Method | RT of the component peaks in the assay sample preparation correspond to those in the assay standard preparation | Super-imposable peaks at RT 3.7, 4.6 and 6.3 -/+ 10% min present in both the assay sample and standard preparations | **COMPLIES** |
| **Dissolution** | HPLC | Adopted In-House Method | No tablet less than 80% [n=6] | Lamivudine 101.0% (RSD=1.6%, n=6) | **COMPLIES:COMPLIES:COMPLIES** |
| **Dissolution** | HPLC | Adopted In-House Method | No tablet less than 80% [n=6] | Nevirapine 96.0% (RSD=4.1%, n=6) | **COMPLIES:COMPLIES:COMPLIES** |
| **Dissolution** | HPLC | Adopted In-House Method | No tablet less than 80% [n=6] | Zidovudine 96.0% (RSD=1.0%, n=6) | **COMPLIES:COMPLIES:COMPLIES** |
| **Assay** | HPLC | Adopted In-House Method | 90.0% - 110.0% | Lamivudine 101.5% (RSD=0.3%, n=9) | **COMPLIES:COMPLIES:COMPLIES** |
| **Assay** | HPLC | Adopted In-House Method | 90.0% - 110.0% | Nevirapine 100.1% (RSD=0.6%, n=9) | **COMPLIES:COMPLIES:COMPLIES** |
| **Assay** | HPLC | Adopted In-House Method | 90.0% - 110.0% | Zidovudine 96.7% (RSD=0.4%, n=9) | **COMPLIES:COMPLIES:COMPLIES** |

**CONCLUSION:** The product complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
| ANALYST: | DR. J. CHEPCHUMBA |  | DATE:09-05-2016 |
| REVIEWER: | DR. G. WANG'ANG'A |  | DATE:16-05-2016 |
| ANALYST: | EMMANUEL TANUI |  | DATE:05-23-2016 |
| DIRECTOR: | HEZEKIAH CHEPKWONY |  | DATE:05-30-2016 |